Kdm2a inhibition in skeletal muscle improves metabolic flexibility in obesity
January 27, 2025 / Kdm2a Inhibitation / Skeletal Muscle Metabolism / Obesity / Insulin Resistance
Inhibiting Kdm2a in skeletal muscle increases slow-twitch myofibers, enhancing metabolic flexibility and lipid utilization. This protects against obesity, insulin resistance, and metabolic stress by modulating H3K36me2 levels and Esrrg mRNA splicing.
What causes behavioral side effects in popular weight loss drugs?
January 23, 2025 / GLP1R Genetic Variations / Cardiometabolic Traits and Obesity / Type 2 Diabetes Treatment Insights
GLP1R genetic variants affect cardiometabolic traits like BMI and blood pressure but show no direct link to behavioral side effects in GLP1RA therapies. GLP1RA use is likely safe for mental health, though further research is needed.
Obesity medications can tackle metabolic cardiorenal disease
January 22, 2024 / GLP-1 Receptor Agonists and CKD / Semaglutide / Metabolic Cardiorenal Disease
GLP-1 receptor agonists and SGLT2 inhibitors address metabolic cardiorenal disease by reducing visceral fat, improving kidney function, and lowering cardiovascular risks. The FLOW trial highlights semaglutide’s efficacy in slowing CKD progression and reducing adverse outcomes.
Weight-Loss Surgery Lowers Risk of Developing Complications of Liver Disease in Patients with Cirrhosis and Obesity
January 27, 2025 / Bariatric Surgery / Liver Disease / MASH-related Cirrhosis Treatment / Obesity / Liver Complications
The SPECCIAL study demonstrates that bariatric surgery reduces the risk of serious liver complications by 72% and progression to decompensated cirrhosis by 80% in patients with obesity and compensated MASH-related cirrhosis, offering an effective treatment option.
GLP-1s for weight loss have heart benefits, too
January 22, 2024 / GLP-1 Medications for Weight Loss / Cardiovascular Benefits / Wegovy / Ozempic / Obesity
GLP-1 medications, like Wegovy and Ozempic, support weight loss, improve cardiometabolic health, and reduce major cardiovascular events in patients with obesity. They work by curbing appetite, enhancing blood sugar regulation, and reducing visceral fat.
Machine Learning-Based predictive model for adolescent metabolic syndrome: Utilizing data from NHANES 2007–2016
January 25, 2025 / Machine Learning / Metabolic Syndrome / Adolescent MetS Risk Prediction
A machine learning-based predictive model using NHANES 2007–2016 data accurately predicts adolescent metabolic syndrome (MetS) risk without requiring biochemical tests. This tool facilitates large-scale, non-invasive screening and early intervention, promoting better public health outcomes for adolescents.
The lean body mass to visceral fat mass ratio is negatively associated with cardiometabolic disorders: a cross-sectional study
January 27, 2024 / Cardiometabolic Health / Obesity / Metabolic Disorders / Visceral Fat / Cardiometabolic Risk / Diabetes Prevention
This study found that a higher lean body mass to visceral fat mass ratio (LMI/VFMI) is inversely associated with cardiometabolic disorders like dyslipidemia, hypertension, and diabetes. Maintaining an optimal LMI/VFMI ratio may improve metabolic health.
Non-industrialized diet improves health and reduces disease risk
January 23, 2025 / NiMe Diet Health Benefits / Gut Microbiome and Diet / Cardiometabolic Health / Weight Loss
The NiMe™ diet, inspired by non-industrialized diets, promotes gut microbiome diversity, reduces inflammation, and improves cardiometabolic health. Rich in plant-based, fiber-rich foods and low in processed items, it offers significant health benefits without calorie reduction.
Muscle fat infiltration predicts heart disease risk better than BMI, study finds
January 21, 2025 / Muscle Fat Infiltration / Heart Disease / IMAT / Cardiovascular Risk / Coronary Microvascular Dysfunction Predictors
A study found skeletal muscle fat infiltration (IMAT) to be a stronger predictor of coronary microvascular dysfunction (CMD) and cardiovascular risk than BMI. IMAT’s inflammatory role links it to metabolic dysfunction and adverse heart health outcomes.
New bill aims to introduce national obesity prevention and management system
January 24, 2024 / National Obesity Management Bill / Obesity Prevention / Korea / Public Health / Disease Management
A proposed bill in Korea aims to establish a national system for obesity prevention and management, addressing its rising prevalence and associated diseases. The law would enable research, prevention, and treatment initiatives to reduce obesity-related public health burdens.
Exploring Growth Opportunities with Lindora in the Longevity-Focused Market
January 27, 2024 / Lindora / Metabolic Health Services / Medically-guided Weight Loss Solutions / Metabolic Health
Lindora, now under Xponential Fitness, is expanding its longevity-focused metabolic health services, offering franchisees opportunities in weight-loss medications, hormone therapy, and IV hydration. Its medically-guided model aligns with growing consumer demand for long-term wellness solutions.
Responding to Rise of Metabolic Liver Disease in Connecticut
January 27, 2025 / Metabolic Liver Disease / MASLD and MASH Awareness / Metabolic Dysfunction / Liver Health
The rise of MASLD and MASH in Connecticut has prompted a working group to recommend public health initiatives, including education, screening, and advocacy programs. These efforts aim to improve liver disease awareness, early detection, and health outcomes statewide.
New advances in novel pharmacotherapeutic candidates for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) between 2022 and 2024
January 27, 2025 / MASH Pharmacotherapeutic Advances / Resmetirom for Liver Disease / Metabolic Liver Disease Treatment
Advances in MASH treatment from 2022–2024 highlight promising pharmacotherapies like resmetirom and others in phase II/III trials. These drugs target fibrosis and necroptosis with improved efficacy and safety, offering hope for tailored therapies in diverse patient populations.
Amplifying Impact: Efruxifermin Plus GLP-1RA Elevates MASH Outcomes
January 27, 2025 / Efruxifermin / GLP-1RA Dual Therapy / MASH and Fibrosis Treatment Advances / Metabolic Liver Disease / Hepatic Fat Reduction Therapy
Efruxifermin (EFX) combined with GLP-1RAs significantly reduces hepatic fat, fibrosis, and metabolic dysfunction in MASH and type 2 diabetes patients. This dual therapy is safe, well-tolerated, and shows promise for accelerating MASH resolution and fibrosis regression.
Akero Rebounds as Benefit Deepens in Key Mid-Stage MASH Trial
January 27, 2025 / Efruxifermin Phase Iib Results / MASH / Liver Cirrhosis Treatment
Akero’s efruxifermin demonstrated significant long-term benefits in reducing liver fibrosis in advanced MASH patients during the Phase IIb SYMMETRY trial. Results showed a 39% improvement at 96 weeks, offering hope for patients with limited treatment options.
Strong heart, strong bones: How cardiovascular health influences bone density
January 22, 2025 / Cardiovascular Health / Bone Density / Bone Mineral Density / Metabolic Health / Heart Health / Skeletal Strength
A study found a strong positive correlation between cardiovascular health, measured by Life’s Essential 8 (LE8), and bone mineral density (BMD). Improved LE8 scores, particularly in younger adults and women, enhance BMD at multiple sites, promoting overall musculoskeletal health.
The Interplay Between Adipokines and Body Composition in Obesity and Metabolic Diseases
January 27, 2025 / Adipokines / Metabolic Health / Obesity-related Inflammation Biomarkers / Insulin Resistance / Obesity Treatment
Adipokines, bioactive molecules from adipose tissue, regulate metabolism, inflammation, and insulin sensitivity. Obesity disrupts adipokine function, leading to insulin resistance and chronic inflammation. Targeting adipokine pathways offers promising therapeutic options for managing metabolic diseases and obesity-related conditions.
Clinical and biochemical factors associated with amygdalar metabolic activity
January 25, 2024 / Amygdalar Metabolic Activity / CVD / Stress Biomarkers / Type 2 Diabetes / Psychological Stress / Cardiovascular Risk
Amygdalar metabolic activity, evaluated via FDG-PET, correlates with fasting plasma glucose (FPG) and coronary artery disease (CAD) history. In type 2 diabetes patients, improved glycemic control reduces metabolic activity, indicating stress regulation’s role in cardiovascular risk.
Know These 4 Core Factors to Avoid a Heart Health Syndrome
January 27, 2024 / Cardiovascular-kidney-metabolic syndrome prevention / Heart Health / Blood Pressure / CKM Syndrome / Metabolic Health / Blood Sugar Control / Kidney Disease Prevention
Cardiovascular-kidney-metabolic (CKM) syndrome, a cluster of heart, kidney, and metabolic disorders, can be prevented by managing four core health factors: blood pressure, cholesterol, body weight, and blood sugar, through lifestyle changes and regular monitoring.